Research Hive is a medical coordination tool for clinical trial teams to manage patient referrals and study documentation on iOS and Android.
The App DNA
What makes this app unique?
The platform removes the manual administrative burden of tracking trial candidates, which displaces fragmented paper-based or spreadsheet-reliant referral processes.
For Clinical research coordinators, physicians, and pharmaceutical trial teams.
What does it look like?
Key features
Enables coordinators to track and send patient referrals to research teams with minimal manual input, acting as a B2B efficiency unlock.
Configurable sharing of SAEs, study updates, and documents among team members, ensuring HIPAA compliance as a core security barrier.
How much does it cost?
Listed as free on both platforms, but the business model relies on B2B partnerships with research sites and pharmaceutical sponsors.
Velocity
Maintenance developmentperformanceUX improvementsShow more...
Research Hive is currently in a maintenance phase, with only two releases identified in the recent window and no updates occurring in the last 111 days. Development focus is limited to security hardening, performance stability, and bug fixes rather than new feature expansion. The lack of recent activity suggests a stable, low-touch product lifecycle. Future updates are expected to remain infrequent, focusing primarily on technical debt and platform compatibility.
Who built it?
User Sentiment
What do users think recently?
Review voice lately leans upset.
How are ratings & reviews evolving?
What users say, by theme
- New users cannot find a registration interface to create an account and begin using the application
1 of 1 recent reviews analyzed · limited sample
Read the full review analysisUnlock 1 user request, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for Research Hive
How's the Medical market?
Research Hive operates in the medical software space with a 4.5-star rating across 8 total ratings. The lack of recent feature updates and the absence of a clear registration path suggest a maintenance-heavy posture rather than active market expansion.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Research Hive
Where is it heading?
The clinical research software market is consolidating around platforms that offer seamless, self-serve onboarding for research coordinators. Research Hive's current maintenance posture and registration friction leave it exposed to more agile competitors that prioritize user-accessible workflows.
- The 111-day gap since the last store update indicates a maintenance-only cadence, which limits the ability to respond to user registration complaints.
- The inability of new users to locate the registration interface directly suppresses the active user base and limits potential B2B partnership growth.
The SWOT
- HIPAA-compliant architecture provides a defensible security barrier for clinical data
- Automated patient follow-up reminders could increase trial enrollment quality
Next best moves
Rebuild registration flow because user feedback identifies it as the primary barrier to entry → increase new-user activation
+ 1 more prioritized moveThe counter-intuitive read
The lack of a public-facing registration flow may…
Read the full takeSince the last report: The platform's strategic outlook has evolved from a passive maintenance posture to a more defined, albeit still constrained, development roadmap. While the registration barrier remains, the inclusion of new product opportunities and a more nuanced interpretation of the onboarding flow mark a shift in analytical focus.
Bottom line
The platform serves a clear operational need in clinical trials, but the registration friction invalidates the current acquisition funnel. Addressing the sign-up path would unlock the user base, whereas continuing in maintenance mode risks losing the market to more accessible competitors.
Unlock 1 critical friction, 1 market threat, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
Report last updated